Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306

BACKGROUND: Ibrexafungerp is a novel antifungal treatment for acute vulvovaginal candidiasis (VVC). Using pooled data from two phase three studies (VANISH 303 and 306) in the treatment of acute VVC, this analysis sought to determine the effectiveness of ibrexafungerp in various patient subgroups tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Goje, Oluwatosin, Sobel, Ryan, Nyirjesy, Paul, Goldstein, Steven R., Spitzer, Mark, Faught, Brooke, Larson, Shelagh, King, Thomas, Azie, Nkechi E., Angulo, David, Sobel, Jack D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc., publishers 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940793/
https://www.ncbi.nlm.nih.gov/pubmed/36255448
http://dx.doi.org/10.1089/jwh.2022.0132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940793/
https://www.ncbi.nlm.nih.gov/pubmed/36255448
http://dx.doi.org/10.1089/jwh.2022.0132

Ejemplares similares